MCT4 inhibits the progress of NAFLD in vivo. (IMAGE)
Caption
A NAFLD model was built as described. Ad-MCT4 or Ad-GFP was intrahepatically injected once every 5 days. The mice were sacrificed at week 8. (A) The dynamic weight changes of mice. ∗∗P < 0.01, ∗P < 0.05, HFD + Ad-MCT4 versus HFD + Ad-GFP. (B) The retrieved liver tissues were subjected to oil red O staining. Representative positive stains are indicated with black arrows (400 ×). (C) Total RNA was isolated from the liver tissues of the mice and touchdown-quantitative PCR analysis of the expression of the genes involved in lipolysis and lipogenesis, and transcriptional regulation. The expression of each target gene was calculated as a relative expression to Gapdh. ∗∗P < 0.01, ∗P < 0.05, HFD + Ad-MCT4 versus HFD + Ad-GFP. (D) The cellular triglyceride (TG), free fatty acid (FFA), glucose (Glu), lactate (LA), and pyruvate (PA) levels were measured. ∗∗P < 0.01, ∗P < 0.05, HFD + Ad-MCT4 versus HFD + Ad-GFP. Each assay condition was done in triplicate, and representative images were shown. MCT4, monocarboxylate transporter 4; NAFLD, non-alcoholic fatty liver disease; HFD, high-fat diet.
Credit
Genes & Diseases
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND